Results 51 to 60 of about 5,337 (191)

Aducanumab: a new phase in therapeutic development for Alzheimer’s disease? [PDF]

, 2021
On 7 June, the FDA approved aducanumab, the first new drug for Alzheimer’s disease in almost 20 years—and notably, the first drug with a putative disease‐modifying mechanism for the treatment of this devastating disorder, namely the removal of β‐amyloid (
Jonathan M Schott, Schott, JM, Bart De Strooper, John Hardy, Hardy, J, Lalli, G, De Strooper, B, Giovanna Lalli   +7 more
core   +1 more source

Aducanumab Use in Symptomatic Alzheimer Disease Evidence in Focus: Report of the AAN Guidelines Subcommittee.

, 2022
OBJECTIVE: To identify the class of evidence for aducanumab use for the treatment of Alzheimer disease and present clinical considerations regarding use.
Coerver, Katherine, Day, Gregory S., West, Brooks, Scarmeas, Nikolaos, Dubinsky, Richard, Mostacero, Anitra, Wessels, Scott R., Armstrong, Melissa J.   +7 more
core   +1 more source

A real-world pharmacovigilance study of adverse drug reactions associated with lecanemab and aducanumab based on WHO-VigiAccess and FAERS databases

Frontiers in Pharmacology
BackgroundLecanemab and Aducanumab are two novel anti-amyloid beta (Aβ) therapies for Alzheimer’s disease (AD) that have shown promise in slowing cognitive decline. However, their safety profiles remain unclear due to limited real-world evidence.
Haoxiang Hu, Yunhan Zhao, Jiesheng Mao, Jianghai He, Yihan Zhang, Hongyu Ye, Xiaokai Yang   +6 more
doaj   +1 more source

Symptomatic amyloid‐related imaging abnormalities in an APOE ε4/ε4 patient treated with aducanumab

Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring, 2020
Introduction Amyloid‐related imaging abnormalities (ARIA) are a common, dose‐dependent effect of amyloid‐targeting antibodies, strongly associated with the apolipoprotein E (APOE) ε4 allele.
Lawren VandeVrede, Daniel M Gibbs, Mary Koestler, Renaud La Joie, Peter A. Ljubenkov, Karine Provost, David Soleimani‐Meigooni, Amelia Strom, Elena Tsoy, Gil D. Rabinovici, Adam L. Boxer   +10 more
doaj   +1 more source

Amyloid-Related Imaging Abnormalities With Anti-amyloid Antibodies for the Treatment of Dementia Due to Alzheimer's Disease

Frontiers in Neurology, 2022
Second-generation anti-amyloid monoclonal antibodies are emerging as a viable therapeutic option for individuals with prodromal and mild dementia due to Alzheimer's disease (AD).
Charles G. Withington, R. Scott Turner
doaj   +1 more source

Near‐Infrared Fluorescent PROTAC Enables Theranostic Imaging and Selective Tau Degradation in Alzheimer's Disease

Advanced Science, EarlyView.
Here, we report a novel NIR fluorescent PROTAC platform that enables real‐time imaging and targeted degradation of Alzheimer's p‐Tau. Our lead compound effectively clears p‐Tau, reduces APP/Aβ, and alleviates cognitive deficits in AD mice. This work demonstrates a theranostic strategy for visualizing degradation and developing next‐generation AD ...
Ziwei Ren, Qian Yue, Ning Gao, Qiu‐Lian Hao, Yan Huo, Chuchu Li, Xinyue Leng, Lu‐Lu Sun, Maggie Pui Man Hoi, Hai‐Hao Han, Mingliang Ma, Xu‐Wen Li   +11 more
wiley   +1 more source

Subcortical signal alteration of corticospinal tracts. A radiologic manifestation of ARIA: A case report

Radiology Case Reports, 2023
Patients with Alzheimer's disease who have been given monoclonal antibodies targeting amyloid-β (Aβ) (eg, gantenerumab, donanemab, lecanemab, and aducanumab) for scientific purposes may have a spectrum of imaging findings known as amyloid-related imaging
Houman Sotoudeh, MD, Mohammadreza Alizadeh, MD, Ramin Shahidi, MD, Parnian Shobeiri, MD, MPH, Natelson love, MD, Aparna Singhal, MD   +5 more
doaj   +1 more source

Molecular Glue Degraders Enhance CAPRIN1‐Dependent Lysosomal Degradation of APP and Reduce Amyloid β in Alzheimer's Disease

Advanced Science, EarlyView.
A new class of lysosome‐directed molecular glue degraders selectively enhance CAPRIN1–APP interactions, driving APP degradation and reducing amyloid‐β production in human neurons and Alzheimer's disease mouse models. This CAPRIN1‐dependent targeted protein degradation strategy reveals a previously unrecognized therapeutic approach for disrupting the ...
Sunghan Jung, Xu Wang, Bin Liu, Raktim Roy, Nancy Jaiswal, Ratan K. Rai, Yuichiro Takagi, Cen Gao, Lifan Zeng, Ho‐Yin Lo, Reagan K. Wohlford, Ryan K. Higgins, Bruce T. Lamb, Anantha Shekhar, Anita C. Bellail, Chunhai Hao   +15 more
wiley   +1 more source

Cost-effectiveness analysis of aducanumab versus placebo for patients with mild cognitive impairment and mild Alzheimer’s disease

BMJ Open
Objectives To assess the cost-effectiveness of aducanumab at its updated price for treating patients with mild cognitive impairment (MCI) and mild Alzheimer’s disease (AD).Design Cost-effectiveness analysis.Settings A five-state Markov model was ...
Minghui Li, Jing Yuan, Z Kevin Lu, Xiaomo Xiong, Gang Lv, Jacob Jordan King   +5 more
doaj   +1 more source

Connecting the dots: A narrative review of the relationship between heart failure and cognitive impairment

ESC Heart Failure, Volume 12, Issue 2, Page 1119-1131, April 2025.
Abstract Large clinical data underscore that heart failure is independently associated to an increased risk of negative cognitive outcome and dementia. Emerging evidence suggests that cerebral hypoperfusion, stemming from reduced cardiac output and vascular pathology, may contribute to the largely overlapping vascular dementia and Alzheimer's disease ...
Mauro Massussi, Maria Giulia Bellicini, Marianna Adamo, Andrea Pilotto, Marco Metra, Alessandro Padovani, Riccardo Proietti   +6 more
wiley   +1 more source